NASDAQ:ZBIO Zenas Biopharma (ZBIO) Stock Price, News & Analysis $10.46 +1.23 (+13.33%) As of 12:36 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Zenas Biopharma Stock (NASDAQ:ZBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zenas Biopharma alerts:Sign Up Key Stats Today's Range$9.31▼$10.8950-Day Range$6.77▼$11.9252-Week Range$5.83▼$26.25Volume90,043 shsAverage Volume180,493 shsMarket Capitalization$437.58 millionP/E RatioN/ADividend YieldN/APrice Target$36.67Consensus RatingBuy Company OverviewZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.Read More… Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zenas Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ZBIO Stock News HeadlinesThe Gross Law Firm Notifies Shareholders of Zenas BioPharma, Inc. (ZBIO) of a Class Action Lawsuit and an Upcoming DeadlineMay 29 at 12:24 PM | globenewswire.comZenas BioPharma to Present at the Jefferies Global Healthcare ConferenceMay 29 at 7:05 AM | globenewswire.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 29, 2025 | Brownstone Research (Ad)Shareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIOMay 29 at 5:45 AM | prnewswire.comZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitMay 28 at 4:00 PM | globenewswire.comZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 28 at 11:25 AM | prnewswire.comZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIOMay 28 at 9:31 AM | prnewswire.comZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How to Lead the Class Action Against Zenas BioPharma, Inc.May 27 at 8:52 PM | prnewswire.comSee More Headlines ZBIO Stock Analysis - Frequently Asked Questions How have ZBIO shares performed this year? Zenas Biopharma's stock was trading at $7.90 on January 1st, 2025. Since then, ZBIO stock has increased by 25.9% and is now trading at $9.95. View the best growth stocks for 2025 here. How were Zenas Biopharma's earnings last quarter? Zenas Biopharma Inc (NASDAQ:ZBIO) announced its earnings results on Thursday, May, 15th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($1.15) by $0.35. The business had revenue of $10 million for the quarter, compared to analysts' expectations of $5 million. When did Zenas Biopharma IPO? Zenas Biopharma (ZBIO) raised $225 million in an IPO on Friday, September 13th 2024. The company issued 13,235,294 shares at a price of $17.00 per share. Who are Zenas Biopharma's major shareholders? Top institutional shareholders of Zenas Biopharma include Wellington Management Group LLP (2.09%), Charles Schwab Investment Management Inc. (0.28%), Jefferies Financial Group Inc. (0.11%) and Nuveen LLC (0.08%). How do I buy shares of Zenas Biopharma? Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zenas Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zenas Biopharma investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Trade Desk (TTD), Advanced Micro Devices (AMD), BioSig Technologies (BSGM), Ford Motor (F) and Genius Sports (GENI). Company Calendar Last Earnings5/15/2025Today5/29/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZBIO Previous SymbolNASDAQ:ZBIO CIK1953926 WebN/A Phone(857) 271-2954FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$36.67 High Stock Price Target$45.00 Low Stock Price Target$30.00 Potential Upside/Downside+297.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$15 million Price / Sales25.74 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares41,834,000Free FloatN/AMarket Cap$386.13 million OptionableN/A BetaN/A These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.